BioAge Labs, Inc. (BIOA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 744.39k | -- | 1984 |
| Mr. Eric Morgen M.D. | Co-Founder, COO & Director | 632.84k | -- | 1983 |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive VP of Research | 673.99k | -- | 1954 |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer | -- | -- | 1967 |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research | -- | -- | -- |
| Ms. Julie Gammelgard | Senior Vice President of People | -- | -- | -- |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging | -- | -- | -- |
| Dr. Carrie-Lynn Langlais Furr | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Mr. Justin Rebo | Senior Vice President of Translational Aging Biology | -- | -- | -- |
| Mr. BJ Sullivan Ph.D. | Chief Strategy Officer | -- | -- | -- |
BioAge Labs, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 62
Description
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Corporate Governance
Upcoming Events
March 20, 2025 at 8:30 PM UTC
BioAge Labs, Inc. Earnings Date
Recent Events
September 23, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
September 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
September 3, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission